QT Imaging Holdings to Attend Radiological Society of North America 2024 Annual Meeting
QT Imaging Holdings (NASDAQ:QTI) announces its participation in the Radiological Society of North America 2024 Annual Meeting in Chicago, December 1-5, 2024. Dr. Bilal Malik, Chief Science Officer, will present on December 4th at 9:30 am, focusing on Breast Ultrasound Techniques. His presentation will compare quantitative transmission ultrasound imaging with digital breast tomosynthesis (DBT), showcasing results from a multi-reader, multi-case observer study.
The study demonstrates QTI's technology performs comparably to DBT, potentially offering a safe and more accessible option for breast cancer screening and diagnosis.
QT Imaging Holdings (NASDAQ:QTI) annuncia la sua partecipazione al Radiondeology Society of North America 2024 Annual Meeting che si terrà a Chicago dal 1 al 5 dicembre 2024. Il Dr. Bilal Malik, Direttore Scientifico, presenterà il 4 dicembre alle 9:30, con un focus sulle Tecniche di Ecografia Mammaria. La sua presentazione confronterà l'imaging ecografico a trasmissione quantitativa con la tomosintesi digitale del seno (DBT), mostrando i risultati di uno studio multi-lettore e multi-caso.
Lo studio dimostra che la tecnologia di QTI si comporta in modo comparabile alla DBT, offrendo potenzialmente un'opzione sicura e più accessibile per lo screening e la diagnosi del cancro al seno.
QT Imaging Holdings (NASDAQ:QTI) anuncia su participación en la Reunión Anual de la Sociedad Radiológica de América del Norte 2024 en Chicago, del 1 al 5 de diciembre de 2024. El Dr. Bilal Malik, Director Científico, presentará el 4 de diciembre a las 9:30 a.m., centrándose en las Técnicas de Ultrasonido de Mama. Su presentación comparará la imagenología de ultrasonido de transmisión cuantitativa con la tomosíntesis digital de mama (DBT), mostrando los resultados de un estudio con múltiples lectores y múltiples casos.
El estudio demuestra que la tecnología de QTI tiene un rendimiento comparable al de la DBT, ofreciendo potencialmente una opción segura y más accesible para el tamizaje y diagnóstico del cáncer de mama.
QT Imaging Holdings (NASDAQ:QTI)는 2024년 12월 1일부터 5일까지 시카고에서 열리는 북미 방사선 학회 연례 회의에 참여한다고 발표했습니다. 수석 과학 책임자인 빌랄 말릭 박사는 12월 4일 오전 9시 30분에 유방 초음파 기술에 대한 발표를 할 예정입니다. 그의 발표에서는 정량적 전송 초음파 영상과 디지털 유방 토모신세시스 (DBT)를 비교하며, 다수의 독립 독자와 다수의 사례 연구 결과를 선보일 것입니다.
이 연구는 QTI의 기술이 DBT에 비해 유사한 성과를 보여주며, 유방암 검진 및 진단을 위한 안전하고 더 접근 가능한 옵션을 제공할 가능성을 시사합니다.
QT Imaging Holdings (NASDAQ:QTI) annonce sa participation à la Réunion Annuelle de la Société Radiologique d'Amérique du Nord 2024 qui se tiendra à Chicago du 1er au 5 décembre 2024. Le Dr Bilal Malik, Responsable Scientifique, présentera le 4 décembre à 9h30, mettant l'accent sur les Techniques d'Échographie du Sein. Sa présentation comparera l'imagerie ultrasonore de transmission quantitative avec la tomosynthèse numérique du sein (DBT), montrant les résultats d'une étude impliquant plusieurs lecteurs et plusieurs cas.
L'étude démontre que la technologie de QTI fonctionne de manière comparable à la DBT, offrant potentiellement une option sûre et plus accessible pour le dépistage et le diagnostic du cancer du sein.
QT Imaging Holdings (NASDAQ:QTI) gibt seine Teilnahme an der Jahrestagung der Radiologischen Gesellschaft Nordamerikas 2024 in Chicago vom 1. bis 5. Dezember 2024 bekannt. Dr. Bilal Malik, Chief Science Officer, wird am 4. Dezember um 9:30 Uhr über Ultraschalltechniken der Brust präsentieren. Seine Präsentation wird die quantitative Übertragungsultraschallbildgebung mit digitaler Brusttomosynthese (DBT) vergleichen und Ergebnisse aus einer Mehr-Lesert- und Mehr-Fall-Beobachtungsstudie vorstellen.
Die Studie zeigt, dass die Technologie von QTI vergleichbare Ergebnisse wie DBT liefert und potenziell eine sichere und zugänglichere Option für das Screening und die Diagnose von Brustkrebs bieten könnte.
- None.
- None.
Dr. Bilal Malik will deliver a presentation on December 4th during the 9:30 am session on Breast Ultrasound Techniques. His talk titled: “Assessing Non-inferiority of quantitative transmission (QT) ultrasound imaging compared with digital breast tomosynthesis (DBT): Results from multi-reader, multi-case (MRMC) observer study”, will highlight the comparative performance of QTI’s and DBT technologies in breast imaging, with an emphasis on findings from the MRMC study that support the potential of QTI as a reliable and effective alternative for breast cancer screening and diagnosis. “Our study represents a major milestone in breast imaging,” said Dr. Malik. “By demonstrating that QTI performs on par with DBT, we are opening the door to safe, more accessible, and patient-friendly diagnostic option.” Additional details will be shared during the presentation.
About QT Imaging Holding, Inc.
QT Imaging Holdings, Inc. is a public (NASDAQ: QTI) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient’s experience. For more information on QT Imaging Holdings, Inc., please visit the company’s website at www.qtimaging.com.
Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241121664478/en/
For media inquiries, please contact:
Susan Schaffler
Head of Communications
Susan.Schaffler@qtimaging.com
Stas Budagov
Chief Financial Officer
Stas.Budagov@qtimaging.com
Source: QT Imaging Holdings, Inc.
FAQ
When is QT Imaging (QTI) presenting at RSNA 2024?
What will QT Imaging (QTI) present at RSNA 2024?
Who will represent QT Imaging (QTI) at RSNA 2024?
What are the key findings of QT Imaging's (QTI) MRMC study?
